Camilo Villaman
Research Subjects
Camilo Villaman has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Jesus Martín Martín
Laboratorio de Redes Biológicas, Fundación Ciencia & Vida, Santiago, Chile
1 shared publication - Alicia Colombo
Department of Basic and Clinical Oncology (DOBC), Faculty of Medicine, University of Chile, Santiago, Chile
1 shared publication - América V. Campos
Cancer Research UK Scotland Institute, Glasgow G61 1BD, UK
1 shared publication - Ana María Carrasco
Fundación Arturo López Pérez, Santiago 7500921, Chile
1 shared publication - Brock Kingstad-Bakke
Department of Basic and Clinical Oncology, Faculty of Medicine, Universidad de Chile, Santiago 8330015, Chile
1 shared publication - Carolina Bizama
Department of Pathology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
1 shared publication
Latest Publications
- Open Access
HPV-18-Immortalised Cells Require the Downregulation of the SncmtRNA-2/Hsa-miR-620 Axis During Cell Transformation
Background and Objectives: Non-coding RNAs (ncRNAs) are genetic transcripts that do not produce proteins but are increasingly recognised for their roles in cellular processes and disease. Specifically, ncRNAs are implicated in the landscape activation of molecular triggers for different diseases, including cancer and viral infections. The function of Sense non-coding mitochondrial RNA-2 (SncmtRNA-2) is currently unknown. This study aims to investigate the roles of SncmtRNA-2 and hsa-miR-620 in Ras-induced cellular transformation. Materials and Methods: The study utilized isoforms V, K, and H of the Ras oncogene and analysed the expression of SncmtRNA-2 and hsa-miR-620 in response to Ras activity. Additionally, both in silico and in vitro analyses were performed to assess whether PML mRNA is a putative target of hsa-miR-620 although direct binding to the PML 3′UTR was not experimentally tested. Results: The research demonstrated that transformation induced by Ras isoforms V, K, and H resulted in decreased expression of both SncmtRNA-2 and hsa-miR-620. Further investigation revealed that hsa-miR-620 is produced by the processing of SncmtRNA-2. It was also shown that Ras increases the expression of Promyelocytic Leukemia Protein (PML). In silico prediction combined with miR-620 gain and loss of function experiments supports PML as a putative hsa-miR-620 target. Conclusions: Ras promotes cellular transformation by decreasing the expression of SncmtRNA-2 and hsa-miR-620, which may contribute to increased PML expression, suggesting but not demonstrating a possible regulatory relationship among these molecules in HPV-immortalised cells. These results highlight a potential SncmtRNA-2/miR-620/PML axis that requires further validation through direct interaction assays and functional necessity/sufficiency experiments.
Open AccessHPV-18-Immortalised Cells Require the Downregulation of the SncmtRNA-2/Hsa-miR-620 Axis During Cell Transformation
Background and Objectives: Non-coding RNAs (ncRNAs) are genetic transcripts that do not produce proteins but are increasingly recognised for their roles in cellular processes and disease. Specifically, ncRNAs are implicated in the landscape activation of molecular triggers for different diseases, including cancer and viral infections. The function of Sense non-coding mitochondrial RNA-2 (SncmtRNA-2) is currently unknown. This study aims to investigate the roles of SncmtRNA-2 and hsa-miR-620 in Ras-induced cellular transformation. Materials and Methods: The study utilized isoforms V, K, and H of the Ras oncogene and analysed the expression of SncmtRNA-2 and hsa-miR-620 in response to Ras activity. Additionally, both in silico and in vitro analyses were performed to assess whether PML mRNA is a putative target of hsa-miR-620 although direct binding to the PML 3′UTR was not experimentally tested. Results: The research demonstrated that transformation induced by Ras isoforms V, K, and H resulted in decreased expression of both SncmtRNA-2 and hsa-miR-620. Further investigation revealed that hsa-miR-620 is produced by the processing of SncmtRNA-2. It was also shown that Ras increases the expression of Promyelocytic Leukemia Protein (PML). In silico prediction combined with miR-620 gain and loss of function experiments supports PML as a putative hsa-miR-620 target. Conclusions: Ras promotes cellular transformation by decreasing the expression of SncmtRNA-2 and hsa-miR-620, which may contribute to increased PML expression, suggesting but not demonstrating a possible regulatory relationship among these molecules in HPV-immortalised cells. These results highlight a potential SncmtRNA-2/miR-620/PML axis that requires further validation through direct interaction assays and functional necessity/sufficiency experiments.
- Open Access
- 8 September 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (9) , 899
Validation of an NGS Panel Designed for Detection of Actionable Mutations in Tumors Common in Latin America
Next-generation sequencing (NGS) is progressively being used in clinical practice. However, several barriers preclude using this technology for precision oncology in most Latin American countries. To overcome some of these barriers, we have designed a 25-gene panel that contains predictive biomarkers for most current and near-future available therapies in Chile and Latin America. Library preparation was optimized to account for low DNA integrity observed in formalin-fixed paraffin-embedded tissue. The workflow includes an automated bioinformatic pipeline that accounts for the underrepresentation of Latin Americans in genome databases. The panel detected small insertions, deletions, and single nucleotide variants down to allelic frequencies of 0.05 with high sensitivity, specificity, and reproducibility. The workflow was validated in 272 clinical samples from several solid tumor types, including gallbladder (GBC). More than 50 biomarkers were detected in these samples, mainly in BRCA1/2, KRAS, and PIK3CA genes. In GBC, biomarkers for PARP, EGFR, PIK3CA, mTOR, and Hedgehog signaling inhibitors were found. Thus, this small NGS panel is an accurate and sensitive method that may constitute a more cost-efficient alternative to multiple non-NGS assays and costly, large NGS panels. This kind of streamlined assay with automated bioinformatics analysis may facilitate the implementation of precision medicine in Latin America.
- 8 September 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (9) , 899
Open AccessValidation of an NGS Panel Designed for Detection of Actionable Mutations in Tumors Common in Latin America
Next-generation sequencing (NGS) is progressively being used in clinical practice. However, several barriers preclude using this technology for precision oncology in most Latin American countries. To overcome some of these barriers, we have designed a 25-gene panel that contains predictive biomarkers for most current and near-future available therapies in Chile and Latin America. Library preparation was optimized to account for low DNA integrity observed in formalin-fixed paraffin-embedded tissue. The workflow includes an automated bioinformatic pipeline that accounts for the underrepresentation of Latin Americans in genome databases. The panel detected small insertions, deletions, and single nucleotide variants down to allelic frequencies of 0.05 with high sensitivity, specificity, and reproducibility. The workflow was validated in 272 clinical samples from several solid tumor types, including gallbladder (GBC). More than 50 biomarkers were detected in these samples, mainly in BRCA1/2, KRAS, and PIK3CA genes. In GBC, biomarkers for PARP, EGFR, PIK3CA, mTOR, and Hedgehog signaling inhibitors were found. Thus, this small NGS panel is an accurate and sensitive method that may constitute a more cost-efficient alternative to multiple non-NGS assays and costly, large NGS panels. This kind of streamlined assay with automated bioinformatics analysis may facilitate the implementation of precision medicine in Latin America.